Patients will receive local prophylactic treatment (Diprosone cream) during 8 weeks from the beginning of the EGF-R inhibitors treatment, on the areas of the body susceptible to be affected by folliculitis.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
30
* Start of treatment: as soon as the EGF-R inhibitors treatment begins * Application: On the body area susceptible to be affected by folliculitis, once a day, in the evening * Dosage: Quantity corresponded to around 2 tubes of 30 grams a week on the face, the chest and upper side of the back. There is no maximum dosage. * Period of treatment: 8 weeks
Centre Oscar Lambret
Lille, France
Centre Hospitalier Regional
Lille, France
Centre Hospitalier Régional
Lille, France
To reduce by 30 % the frequency of folliculitis by a local corticotherapy beginning at the same time that the treatment by EGF-R inhibitors began
Time frame: 2 months of treatment by corticotherapy
To assess the frequency of grade I, II and III folliculitis under Cetuximab and under Erlotinib
Time frame: 2 months of treatment
To list the cutaneous side effects of the EGF-R inhibitors
Time frame: 2 months of treatment
To assess the patient quality of life with the DLQI questionnaire
Time frame: 2 months of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.